Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy

Abstract

Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin lymphoma (NHL), accounting for approximately 6% of all NHL cases. Patients with MCL usually present with advanced-stage disease and frequently have refractory and/or relapsed disease following conventional therapies, including chemoimmunotherapy, autologous hematopoietic stem cell transplantation, and targeted therapies, leading to poor survival outcomes. 1 Brexucabtagene autoleucel (brexu-cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, was granted the US Food and Drug Administration approval in 2020 based on the impressive outcomes of the multicenter phase II ZUMA-2 trial 2 in patients with relapsed/refractory MCL. Long-term follow-up data of the ZUMA-2 trial have shown remarkable durable responses with an ORR of 91% and complete response (CR) of 68%, even among highrisk groups, after a median follow of 35.6 months. 3 Real-world data from the US lymphoma CAR T consortium and the European Early Access Program have demonstrated remarkable efficacy and similartoxicity profile of brexu-cel, which were comparable to the results reported in the ZUMA-2 trial. 4,5